AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Aug 05, 2021

Will this work?

Exploring data can have a huge impact on patient care.


Peter A. Lio, MD, FAAD
Peter A. Lio, MD, FAAD

Applying an integrative approach to the treatment of common dermatologic diseases involves more than saying, “Let’s try this.” However, that idea — when coupled with solid data — can yield positive results.

Friday’s session, “Integrative Dermatology: What is the Evidence” (S007) will make a case for such an approach, but with a thorough look at the evidence. According to Peter A. Lio, MD, FAAD, who leads the session, data speaks volumes.

“It turns out that there is a fair amount of reasonably high-quality evidence for some integrative approaches for many common dermatologic diseases,” said Dr. Lio, who serves as clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine. Dr. Lio talked to DermWorld Meeting News in anticipation of his upcoming session.

“While, to some extent, the evidence is not to the same level as most conventional therapies, there is no doubt that within dermatology, we have something of a higher tolerance for using off-label treatments.”

In addition to exploring existing data on the use of integrative treatment for common dermatologic diseases, the session will also evaluate the pitfalls and potential dangers or side effects of some of those therapies. Factoring in the patient’s perspective is also important, Dr. Lio said.

In particular, panelists will dive into integrative therapies for atopic dermatitis, warts/molluscum, acne, psoriasis, and rosacea. For example, Dr. Lio said, there’s no doubt that pediatric lichen planus “is a real condition,” and “yet there are exactly zero FDA-approved medications for this.” Likewise, many dermatologists are seeing an increase in the number of patients with lichen planopilaris, another condition with relatively sparse literature. Finally, he said, there is at least some evidence to support therapies such as topical indigo naturalis for psoriasis, topical vitamin B12 for atopic dermatitis, and niacinamide for acne and rosacea.

“While I would charitably say that none of these therapies are going to replace our conventional prescriptions any time soon, there is no doubt that they can all play supportive adjunctive roles for selected patients, and can be very helpful,” Dr. Lio said. “For certain patients, just being open to such approaches can help establish a more powerful therapeutic alliance which can certainly affect patient outcomes.”

Beyond clinical evidence, a general assurance of safety and practicality/accessibility are among the three criteria for considering integrative therapies, Dr. Lio said. In screening for those attributes, such therapies typically have relatively few pitfalls. However, nothing is certain, he said, and “any sword cuts both ways.”

For example, many botanical oils have measurable effects, but can also act as contact sensitizers, he said. Certain herbal preparations can be effective but can also have real, measurable drug interactions that can cause harm. Finally, more sophisticated medical systems such as acupuncture can be difficult to distill down into a practical application for a conventionally based dermatologist to integrate into practice at all.

Sourcing ingredients is another challenging issue that can make one quickly appreciate having a regulatory body like the FDA, Dr. Lio said. Finally, patient expense is extremely important as almost none of these treatments are covered by insurance.

Understanding the patient perspective when recommending an integrative approach is of equal importance, Dr. Lio said. Many patients are interested in alternative medicines, particularly in dermatology. In fact, several studies have reported that some 50% of dermatology patients have tried alternative forms of medicine.

“I think there are several drivers of this phenomenon including a desire to use more ‘natural’ approaches in general, concern about side effects and a real quest for finding and addressing the ‘root cause’ of an illness,” Dr. Lio said.

Arguably, he said, conventional dermatology does some of these well, but perhaps not well enough.

“Part of my ‘hidden agenda’ is to help forge a deeper connection with our patients so we can better understand their hopes, fears, and desired approach, and to engage in a shared decision-making process with them,” he said. “Sometimes, just being open to integrative therapies will help a patient decide to use a conventional treatment.”

 

 

Interesting Stories
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
More in Summer Meeting 2021
Peter Lio, MD, FAAD
Summer Meeting 2021
The secrets of minimizing pain
Aug 11, 2021
Lawrence S. Chan, MD, FAAD
Summer Meeting 2021
Biomedical advancements impact dermatologic diagnosis and treatment
Aug 11, 2021
Todd Schlesinger, MD, FAAD
Summer Meeting 2021
Update on managing advanced skin cancer
Aug 11, 2021
Hensin Tsao, MD, PhD, FAAD
Summer Meeting 2021
HPV vax, psoriasis biologics, and caregiver quality of life highlight FiRST session
Aug 11, 2021
07e
Summer Meeting 2021
Summer Meeting packed a welcome punch
Aug 11, 2021
Mario E. Lacouture, MD, FAAD
Summer Meeting 2021
Oncodermatology takes the stage at Fox Lectureship
Aug 06, 2021
Julie Gerberding, MD, MPH
Summer Meeting 2021
COVID-19: A “predictable surprise”
Aug 06, 2021
Aimee Payne, MD, PhD, FAAD
Summer Meeting 2021
Frost Lectureship traces mPV treatment’s path from lab to clinical trial
Aug 06, 2021
2020 Gold Medal Presentation | Professor R. Rox Anderson, MD (left), Lancer Endowed Chair in Dermatology, Harvard Medical School and Director, Wellman Center for Photomedicine at Mass. General Hospital. 2021 Gold Medal Presentation | Dirk Michael Elston, MD, FAAD (right), Medical University of South Carolina.
Summer Meeting 2021
Two physicians honored with AAD Gold Medal awards
Aug 05, 2021
Alina G. Bridges, DO, FAAD
Summer Meeting 2021
New science, technology, and dedication improve dermatopathology
Aug 05, 2021
Sm21 F008 1526e
Summer Meeting 2021
How to have mindful, effective conversations with patients
Aug 05, 2021
Sergey Rekhtman, MD, FAAD, PharmD, MPH, and Sheila Shaigany, MD, FAAD
Summer Meeting 2021
Lessons from COVID-19’s cutaneous manifestations
Aug 05, 2021
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.